This current study aims to investigate the expression of HDAC-2 by immunohistochemistry in tissue samples from triple negative breast cancer patients and its relationship to the clinicopathological characteristics of the tumor and the prognosis of the patient. The gene discussed is HDAC2; the disease is triple-negative breast carcinoma.